ReviewNature reviews. Urology2022
Germline testing and genetic counselling in prostate cancer.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05681416 (Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics.European urology open science · 2026Article
- From "who to test" to "who benefits": equity-by-design guardrails for prostate cancer germline testing at scale.Familial cancer · 2026Article
- Blueprint for building a patient-centered hereditary cancer program based on stakeholder perspectives.Gynecologic oncology reports · 2026Article
- Article
- Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice.Journal of multidisciplinary healthcare · 2026Review
- The distinct molecular profile of metastatic prostate cancer in the mixed Brazilian population.Genetics in medicine open · 2026Article
- From Diagnosis to Disclosure: Navigating Genetic Counseling Dilemmas inCase reports in genetics · 2026Article
- Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.Current oncology (Toronto, Ont.) · 2025Review
- Quality of life assessment among ethnically diverse Black prostate cancer survivors: a constructivist grounded theory approach.Journal of cancer survivorship : research and practice · 2025Article
- Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry.Nature communications · 2025Article
- Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.JCO precision oncology · 2025Article
- Predicting pathogenic DNA damage repair gene mutations in prostate cancer patients: a multi-center magnetic resonance imaging radiomics study.Quantitative imaging in medicine and surgery · 2025Article
- Genomic medicine and personalized treatment: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Review
- Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.JCO clinical cancer informatics · 2025Article
- The heat of the battle: inflammation's role in prostate cancer development and inflammation-targeted therapies.Discover oncology · 2025Review
- Signet-ring cell carcinoma in rectal malignancies: a case report with an unexpected outcome.Frontiers in oncology · 2025Article
- Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening.Cureus · 2025Article
- Health-related quality of life in ethnically diverse Black prostate cancer survivors: a convergent parallel mixed-methods approach.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- [Molecular tumor boards in uro-oncology-prostate cancer].Urologie (Heidelberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by precision medicine. Rates of germline pathogenic variants have been reported in up to 15% of men with prostate cancer, particularly in metastatic disease, and results of genetic testing could uncover options for precision therapy along with a spectrum of hereditary cancer-predisposition syndromes with unique clinical features that have complex management options. Thus, the pre-test discussion, whether delivered by genetic counsellors or by health-care professionals in hybrid models, involves information on hereditary cancer risk, extent of gene testing, purpose of testing, medical history and family history, potential types of results, additional cancer risks that might be uncovered, genetically based management and effect on families. Understanding precision medicine, personalized cancer risk management and syndrome-related cancer risk management is important in order to develop collaborative strategies with genetic counselling for optimal care of patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.